INTRODUCTION
In patients with type 2 diabetes mellitus Endocrinologists/American College of Endocrinology (AACE/ACE) recommend a stringent HbA 1c target of 6.5% [2] . HbA 1c is influenced by increases in daily measures of glucose levels including fasting plasma glucose (FPG) and postprandial glucose (PPG), which are discrete values for measures of daily glucose levels. In addition, rapid daily fluctuations in glucose levels have been implicated as particularly important in contributing to diabetes-related complications [3] . Because average daily glucose measurements are strongly correlated with HbA 1c [4] and are important parameters for physicians to make therapeutic decisions, and because patients understand FPG and PPG better than HbA 1c [5] , estimation of mean daily glucose parameters is critical. Twenty-four hour mean weighted glucose (MWG) can be used to provide an indication of the mean glucose exposure of the body over an entire day [6] .
The ADA/EASD position statement recommends combination therapy when HbA 1c goals are not achieved or maintained during approximately 3 months with monotherapy [1] . However, uptitration of monotherapy is often practiced rather than addition of another agent [7, 8] , which is delayed by an average 27-35 months [7] . The ADA/EASD and AACE/ACE recommend metformin as first-line drug therapy for T2DM [1, 2] . Metformin is a biguanide that helps maintain glycemic control by suppressing glucose production by the liver [1] .
Gastrointestinal disturbances (diarrhea, nausea, and vomiting) are the most common adverse events reported with metformin monotherapy, although the incidence is lower with metformin extended release (XR) versus metformin immediate release (IR) [9, 10] .
Because T2DM is a progressive disease associated with worsening hyperglycemia, intensification of treatment over time through combination therapy typically becomes necessary for most patients to maintain glycemic goals [1, 11] . After metformin is used, various strategies to achieve glycemic control can be applied. Antidiabetic medications with complementary mechanisms of action and differing safety and tolerability profiles can help improve glycemic outcomes with greater tolerability compared with uptitration of a single antihyperglycemic agent to the maximum dose [1, 12, 13] .
Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor with a mechanism of action complementary to that of metformin. The DPP-4 enzyme is involved in the degradation of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), both of which augment release of insulin from the pancreas in a glucosedependent manner; GLP-1 also decreases pancreatic glucagon secretion. By inhibiting DPP-4 degradation of GLP-1 and GIP, saxagliptin increases insulin secretion and suppresses glucagon release, complementary effects for controlling hyperglycemia [1, 14, 15] . DPP-4 inhibitors may also aid in beta-cell preservation, as suggested by preclinical evidence of inhibition of beta-cell apoptosis and necrosis and stimulation of beta-cell proliferation [16] . Saxagliptin is generally well tolerated for the treatment of T2DM [17] . The most commonly reported adverse events with saxagliptin are upper respiratory tract infection, urinary tract infection, and headache [18] . Saxagliptin is weight neutral and is not associated with hypoglycemia when used as monotherapy [17] ; dose-adjustment from the approved 5-mg dose is not required in patients with hepatic impairment, but dose-reduction is required in patients with moderate to severe renal impairment and when coadministered with strong inhibitors and inducers of cytochrome P450 3A4 and 3A5 isoforms [17] .
Postmarketing reports of pancreatitis have been reported with DPP-4 inhibitors, including saxagliptin [17, 18] .
Saxagliptin has been shown to be efficacious and generally well tolerated as add-on therapy in patients with T2DM inadequately controlled with metformin monotherapy [19, 20] [12] .
Here, findings are presented from a 4-week study in which the clinical effects, including impact on measures of daily glucose control, of adding saxagliptin 5 mg to metformin XR 1,500 mg were compared with those of uptitrating metformin XR to the maximum daily dosage of 2,000 mg in patients with T2DM whose glucose levels were not adequately controlled with metformin monotherapy.
MATERIALS AND METHODS
The study protocol for this international, randomized, double-blind, phase 3b trial was approved by the institutional review board and independent ethics committee at each site, and the study was conducted in accordance with All prior and current medications at screening and concomitant medications taken during the study were recorded. Patients using herbal or over-the-counter glucose-lowering agents were allowed to continue with the medications provided that doses remained stable throughout the study, but they could not begin treatment with these preparations during the study. Antihyperglycemic medications other than study medication were not permitted, with the exception of insulin during a hospitalization for other causes. Potent cytochrome P450 3A4 inducers and HIV antivirals were prohibited. Treatment with any systemic corticosteroid could not be started during the study.
Efficacy Assessments
The primary efficacy end point was the change from baseline to week 4 in 24-h MWG. The 24-h MWG was estimated by dividing the area under the 24-h glucose concentration curve by 24.
The secondary efficacy end points were change from baseline to week 4 in 2-h PPG (2-h after the evening meal) and FPG (immediately before breakfast). The tertiary efficacy end point was the change in HbA 1c from baseline to week 4.
All glucose measurements for assessment of efficacy end points were processed at a central laboratory.
Safety and Tolerability Assessments
All adverse events, serious adverse events, and discontinuations due to adverse events were recorded. Safety and tolerability also were assessed by evaluating changes in 12-lead electrocardiograms (ECGs), vital signs, and clinical laboratory tests.
Statistical Analysis
A sample size of 36 patients per group was estimated to provide 90% power to detect a difference of 18 mg/dL in MWG from baseline to week 4 between the two treatment groups.
Assuming approximately 20% of patients would discontinue without a valid efficacy assessment at week 4, 90 patients needed to be randomized.
The change from baseline to week 4 in 24-h MWG (primary efficacy end point) was analyzed in the randomized data set (all randomized patients who took C1 dose of study medication)
for patients who had a baseline measurement and a post-randomization measurement for the time point analyzed using analysis of covariance (ANCOVA), including treatment group, baseline value, and country in the model.
The change from baseline to week 4 in 2-h PPG (secondary efficacy end point) was analyzed using the same ANCOVA used for the primary efficacy end point. Change from baseline to week 4 in FPG (secondary efficacy end point) was analyzed using ANCOVA, with treatment group, baseline value, and country in the model, and using last-observation-carried-forward methods. The change from baseline to week 4 in HbA 1c (tertiary efficacy end point) was analyzed using ANCOVA, with treatment group, baseline values, and country in the model. Statistical testing of the primary and secondary efficacy end points was conducted sequentially to control the type I error rate at the 0.05 level. Safety analyses are presented descriptively, using data from all patients who took C1 dose of study medication. patients entering the lead-in period; 93 patients were randomized and treated (Fig. 2) . Ninety patients (96.8%) completed the 4-week treatment period. One patient in each group discontinued because they withdrew consent, and 1 patient in the saxagliptin ? metformin XR group died on day 9 from chronic ischemic heart disease with cardiomegaly. This death was not considered by the investigator to be related to study drug. Treatment groups were generally balanced with regard to demographic and baseline clinical characteristics ( to -7.6) for saxagliptin ? metformin XR and -8.2 ± 6.0 mg/dL (95% CI -20.0 to -3.7) for uptitrated metformin XR. The mean ± SE between-group difference was -10.8 ± 7.01 mg/dL (95% CI -24.8 to 3.2; P = 0.1278) for saxagliptin ? metformin XR versus uptitrated metformin XR (Table 2 ). In keeping with the sequential statistical analysis procedure used in this study, because between-group differences in the primary end point did not reach statistical significance, the significance of differences in secondary and tertiary efficacy end points was not calculated.
The 24-h glucose profile was comparable between groups at baseline (Fig. 3a) . At week 4, between-group differences were observed, with lower glucose levels recorded in patients receiving saxagliptin ? metformin XR compared with patients receiving uptitrated metformin XR (Fig. 3b) . The mean change from baseline in 24-h glucose levels at week 4 was generally greater at all but one time point with saxagliptin ? metformin XR than with uptitrated metformin XR (Fig. 3c) .
At week 4, the adjusted mean ± SE change from baseline for 2-h PPG was greater with saxagliptin ? metformin XR than with uptitrated metformin XR (Table 3) ; the mean ± SE between-group difference was -31.1 ± 11.8 mg/dL (95% CI -54.6 to -7.7). For FPG, the adjusted mean ± SE change from baseline was also greater for saxagliptin ?
metformin XR than for uptitrated metformin XR (Table 3) ; the mean ± SE between-group difference was -5.7 ± 7.2 mg/dL (95% CI -20.0 to 8.5). The adjusted mean ± SE change from baseline for HbA 1c was slightly greater for saxagliptin ? metformin XR than for uptitrated metformin XR (Table 3) ; the mean ± SE between-group difference was -0.1 ± 0.1% (95% CI -0.3 to 0.0). During the screening period, the mean HbA 1c decreased in patients that were to be subsequently randomized to the two groups at week -4, after all of these patients were switched to metformin XR 1,500 mg (Fig. 4) Baseline mean ± SE 229.7 ± 9.1 234.0 ± 10.3
Adjusted mean ± SE change from baseline -31.4 ± 9.7 -0. Baseline mean ± SE 8.6 ± 0. Fig. 4 Mean glycated hemoglobin (HbA 1c ) from screening to week 4. MET XR Metformin extended release, SAXA saxagliptin -8.5; P = 0.0001) [22] . Differences in other glycemic measures, including 2-h PPG, mean daily glucose, and 2-day average FPG, were also significantly greater with saxagliptin ?
metformin XR, compared with placebo. In contrast with the current study, the patients in that study did not change their metformin dose during the lead-in period [22] . [12] . In that study, the decrease in HbA 1c at week 18 was significantly greater with saxagliptin ? metformin XR, compared with uptitrated metformin XR (adjusted mean change from baseline, -0.88%
vs -0.35%; 95% CI for difference, -0.73 to -0.31; P\0.0001). In this longer trial, 24-h MWG was not an end point [12] . Given that the design of that study was almost identical to the design of the current study, it is likely that addon therapy with saxagliptin versus uptitration of metformin would have resulted in significant decreases in HbA 1c if the current study had extended beyond 4 weeks. Along with considerations of efficacy, tolerability, and safety, it is also important to include cost-effectiveness as a factor in the decision to add saxagliptin to metformin XR therapy. To the authors knowledge, the costeffectiveness of saxagliptin ? metformin XR, compared with uptitrated metformin XR has yet to be assessed. However, recent studies performed in Germany and Sweden have reported saxagliptin plus metformin to be cost-effective compared with metformin plus sulfonylurea, based on relatively greater improvements in quality-adjusted life years [23, 24] .
The current study is limited in that it presents the outcomes achieved in a small number of patients, examining a nonstandard, mechanistic end point after only 4 weeks of treatment. Therefore, these results may not be applicable to patients receiving longer-term treatment. 
CONCLUSION

